Disease Extent Stratified by PSA at Time of Imaging According to PROMISE (n = 55) (17)
| PSMA PET/CT findings | Total (n = 55) | Pre-PCWG3 PSA: <1.0 ng/mL (n = 21) | Early PCWG3 PSA: 1.0–<2.0 ng/mL (n = 11) | Early EAU PSA: 2.0–≤ 3.0 ng/mL (n = 23) |
| Negative | 14 (25) | 10 (48) | 0 (0) | 4 (17) |
| Tr/N1 only | 16 (29) | 6 (29) | 3 (27) | 7 (30) |
| Local recurrence (Tr) | 9 (16) | 3 (14) | 1 (9) | 5 (22) |
| Pelvic lymph nodes (N1) | 9 (16) | 3 (14) | 2 (18) | 4 (17) |
| Any M1 | 25 (45) | 5 (24) | 8 (73) | 12 (52) |
| Extrapelvic lymph nodes (M1a) | 15 (27) | 3 (14) | 3 (27) | 9 (39) |
| Bone (M1b) | 13 (24) | 3 (14) | 4 (36) | 6 (26) |
| Soft tissue/visceral (M1c) | 2 (4) | 0 (0) | 2 (18) | 0 (0) |
| N/M disease extent | 34 (62) | 8 (38) | 0 (0) | 16 (70) |
| Unifocal (1) | 6 (18) | 2 (25) | 1 (10) | 3 (19) |
| Oligometastatic (2–5) | 17 (50) | 4 (50) | 9 (90) | 4 (25) |
| Multiple or disseminated (≥6) | 11 (32) | 2 (25) | 0 (0) | 9 (56) |
Data are number of patients, followed by percentage in parentheses.